In this article two typographical errors have been identified.
The sentence "At 12 w; significantly higher 15 mg, 30 mg v PBO ACR20 (65 %, 56 % v 48 %) in Table 3 is now corrected into "At 12 w; significantly higher 15 mg, 30 mg v PBO ACR20 (65 %, 56 % v 28%)”.
The study with Abrocitinib (PF-04965842) mentioned in Table 4 was a phase II not a phase III study as erroneously indicated.
The authors would like to apologise for any inconvenience caused.